EXACT Sciences (EXAS) reported a loss of $0.46 per share in its second quarter, beating consensus forecast by 9 cents. The company reported revenue of $21.19 million for the quarter, up 161% on a year-over-year basis. Revenue beat consensus forecast by $2.65 million.
Eli Lilly (LLY) reported its financial results for the second quarter of 2016. For the quarter, the company reported earnings of $0.86 per share, in-line with the consensus forecast. LLY reported revenue of $5.4 billion, up 8.4% on a year-over-year basis. Revenue beat consensus forecast by $250 million.
RedHill Biopharma (RDHL) reported a loss of $0.06 per share in its second quarter. The company ended the quarter with $3.4 million in cash and cash equivalents on its balance sheet.